The record spend that no one can justify
In 2024, the world’s top 2,000 corporate R&D investors spent a combined €1.45 trillion — a nominal record — according to the 2025 EU Industrial R&D Investment Scoreboard. Real growth after inflation: just 4%. The WIPO Global Innovation Index Tracker 2025 projects global R&D growth will slow to 2.3% in 2025 — the weakest expansion since 2010.
More money flowing in. Less confidence it is generating returns. And most companies still lack the tools to answer what any CFO will eventually ask: what did we get for that?
R&D intensity is rising — productivity is not keeping up
The NY Fed January 2025 analysis The R&D Puzzle in U.S. Manufacturing Productivity Growth found R&D intensity has grown steadily since the 1980s while productivity growth has not. McKinsey pharma analysis found industry-level R&D productivity flat since 2012 despite massive investment growth.
Why lagging indicators dominate — and fail
Most companies report two financial metrics: revenue from new products as percent of total revenue, and R&D spend as percent of revenue. McKinsey Taking the Measure of Innovation calls these dangerously limited — lagging indicators that only confirm success after the fact. For industries with long development cycles — industrial equipment, specialty materials, aerospace — this is too late to inform the next decision.
The three gaps that prevent honest measurement
A synthesis of major R&D measurement studies drawing on McKinsey, BCG, and academic research identifies three recurring structural gaps:
- Activity vs. outcome confusion. Most teams track inputs — headcount, spend, patents filed. A patent no one licenses is indistinguishable from a valuable one in most dashboards.
- No universally right metric. BCG Michael Ringel argued that pegging R&D to a fixed percent of revenue is counterproductive. The right level depends on opportunity — but that requires early pipeline visibility, which lagging metrics cannot provide.
- Time horizon mismatch. Budget cycles run annually. Fundamental research returns materialize over 5 to 15 years. Without leading indicators, the connection between today’s investment and tomorrow’s competitiveness stays invisible.
What a better measurement system looks like
The consensus across McKinsey, BCG, and MIT Technology Review analysis of R&D return methodologies points toward portfolio-based measurement. McKinsey recommends dividing R&D into distinct pools: core improvements measured by cost reduction and time-to-market, breakthrough innovations measured by option value, and exploratory ventures measured by learning quality. Early adoption rates, time-to-market signals, and an initiative-to-deliverable map linking each project to business outcomes convert R&D from an opaque cost center into a traceable investment.
The macro context makes this urgent
WIPO notes two consecutive years of declining revenue among the world’s top R&D spenders. Stellantis, Volkswagen, and Mercedes-Benz all cut R&D in 2024. The companies that will protect their innovation budgets are those that can tell finance a coherent measurement story: what is in the pipeline, what it is worth, and what milestones confirm progress.
A practical starting point
The next step is not to chase the one perfect metric, but to build a set of measures that together tell a truer story of how R&D creates value.
McKinsey and BCG synthesis, 2025
Start with an honest audit: list every metric your R&D function reports to the board. Ask for each one — is it leading or lagging? Activity or outcome? Tied to a specific investment decision? Most teams find four or five activity metrics and one financial ratio. The goal is to surround those with earlier signals that make them interpretable.
Diagnose your R&D maturity. This article covers R&D Strategy. Run the free 10-minute Excellence Framework diagnostic to see how your organization scores. Launch Framework →